Vol 13, No 4 (2009)
Original paper
Published online: 2009-07-21
The assessment of plasma visfatin concentration in patients with metabolic syndrome and essential hypertension
Nadciśnienie tętnicze 2009;13(4):258-265.
Abstract
Background Visfatin is recently discovered adipocytokine
preferentially secreted by visceral adipose tissue. The aims
of the study were: estimation of plasma visfatin levels in
patients with metabolic syndrome and essential hypertension,
assessment of correlations between visfatin and blood
pressure values, selected anthropometric and biochemical
parameters.
Material and methods Sixty eight patients were qualified for the study and divided into: group 1 - with metabolic syndrome and hypertension (n = 31), group 2 - with essential hypertension (n = 22), group 3 - control group (n = 15). In all subjects we measured: anthropometric measurements, blood pressure values, fat tissue mass, lipid and glycemic profile. Oral glucose tolerance test (OGTT) and insulin-resistance ratio were estimated. Fasting and postprandial visfatin was measured using ELISA method.
Results Mean plasma fasting visfatin in 3 groups was respectively: group 1 - 1.58 ± 1.88 ng/ml, group 2 - 0.82 ± 0.87 ng/ml, group 3 - 1.69 ± 1.58 ng/ml. Mean postprandial plasma visfatin levels in studied groups was respectively: group 1 - 1.36 ± 1.35 ng/ml, group 2 - 0.63 ± 0.44 ng/ml, group 3 - 0.70 ± 0.32 ng/ml. Significant differences were found in group 1 v. 2 and 3. Fasting plasma visfatin correlated with waist circumference and mean diastolic blood pressure value. No significant linear correlation were found between fasting plasma visfatin and insulin-resistance ratio (IRI/G), fat tissue mass, body mass index, triglicerides, HDL cholesterol and OB. No linear relationship was found between plasma visfatin and glucose level.
Conclusions Visfatin may have impact on modulation of hypertension values. There is no relationship between serum visfatin level, insulin- resistance ratio and fat tissue mass despite positive correlation with waist circumference therefore visfatin can not be indicated as a link between obesity and insulin-resistance or as a predictive factor for diabetes type 2 development.
Material and methods Sixty eight patients were qualified for the study and divided into: group 1 - with metabolic syndrome and hypertension (n = 31), group 2 - with essential hypertension (n = 22), group 3 - control group (n = 15). In all subjects we measured: anthropometric measurements, blood pressure values, fat tissue mass, lipid and glycemic profile. Oral glucose tolerance test (OGTT) and insulin-resistance ratio were estimated. Fasting and postprandial visfatin was measured using ELISA method.
Results Mean plasma fasting visfatin in 3 groups was respectively: group 1 - 1.58 ± 1.88 ng/ml, group 2 - 0.82 ± 0.87 ng/ml, group 3 - 1.69 ± 1.58 ng/ml. Mean postprandial plasma visfatin levels in studied groups was respectively: group 1 - 1.36 ± 1.35 ng/ml, group 2 - 0.63 ± 0.44 ng/ml, group 3 - 0.70 ± 0.32 ng/ml. Significant differences were found in group 1 v. 2 and 3. Fasting plasma visfatin correlated with waist circumference and mean diastolic blood pressure value. No significant linear correlation were found between fasting plasma visfatin and insulin-resistance ratio (IRI/G), fat tissue mass, body mass index, triglicerides, HDL cholesterol and OB. No linear relationship was found between plasma visfatin and glucose level.
Conclusions Visfatin may have impact on modulation of hypertension values. There is no relationship between serum visfatin level, insulin- resistance ratio and fat tissue mass despite positive correlation with waist circumference therefore visfatin can not be indicated as a link between obesity and insulin-resistance or as a predictive factor for diabetes type 2 development.
Keywords: visfatinmetabolic syndromehypertensionvisceral fat tissue